Regado shares pop as drug wins fast-track status

Regado Biosciences ($RGDO) earned a pop in its stock price this morning after it put out word that the FDA has granted fast-track status to its anticoagulant REG1. The Basking Ridge, NJ-based biotech's share price is up more than 20% on Monday morning. "We continue to believe that REG1 has the potential to become a new standard of care for anticoagulation in interventional cardiology," noted CEO David Mazzo in a statement. Release

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.